Searched for
FEBRILE NEUTROPENIA
Zydus to buy Assertio for $166.4 millionZydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structure...- Zydus Lifesciences acquires US pharma firm Assertio for $166 millionIn a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166...
- Lupin gets USFDA nod for biosimilar drugLupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at...
- Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...
- Drug maker Lupin inks licensing pact with Axantia for PegfilgrastimPegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherap...
- Biocon, Mylan launch cancer drug in CanadaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...
- Biocon, Mylan launch cancer drug in AustraliaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...
- Biocon erases gains, tanks nearly 12%Neulasta had US sales of $4.2 billion for the 12 months to March, according to IQVIA.
- Sensex drops 50 pts, Nifty tests 10,600; Biocon jumps 6%S&P BSE Sensex was trading 44.17 points lower at 34,967.72 with HDFC Bank as top gainer.
- Intas Pharma launches its first biosimilar product Accofil in EuropeThe product has recently been introduced under the brand Accofil and has already won two prestigious tenders, in Netherlands and the UK.
- Venus eyes Rs 1,000 crore revenue by FY 2017Venus Remedies aims to launch its major products in global markets with an eye on more than doubling revenues to Rs 1,000 cr by 2016-17.
- Venus Remedies shares rally 10% on Mexico patent for PotentoxVenus Remedies shares rallied nearly 10% in morning trade, after the company received patent from Mexico for its novel antibiotic Potentox.
- Venus Remedies gets Mexico patent for PotentoxGranted by the Mexican Institute of Industrial Property, the patent protects the composition of Potentox, the company said.
- Venus gets US patent for antibiotic productVenus Remedies has got US patent for Potentox, used for pneumonia other infections and is looking at increasing presence in the $ 12 bn ant...
- Venus' second research product in UkrainePharmaceutical company Venus Remedies has received regulatory approval for marketing its second research product in Ukraine.
Load More
